Dr. Jason Spector, Co-Founder, Scientific Advisor and Chairman of the Board
As the inventor of Fesarius Therapeutics patent-pending collagen microsphere technology, Dr. Spector provides significant input to the scientific direction of the company with respect to formulation, pre-clinical and clinical research and ultimate product development. Dr. Spector is a Professor of Surgery and Otolaryngology at Weill Cornell Medicine, and Adjunct Professor in the Meinig School of Biomedical Engineering at Cornell University. He is a nationally-renowned board-certified plastic surgeon at New York-Presbyterian Hospital/Weill Cornell Medicine where he specializes in reconstructive microsurgery. In addition to his clinical responsibilities, Dr. Spector is the Director and Principal Investigator of the Laboratory for Bioregenerative Medicine and Surgery (LBMS) at Weill Cornell Medicine. The LBMS focuses on novel approaches for tissue engineering and wound healing as well as the development of translational technologies from bench to bedside. Dr. Spector invented the patent-pending collagen microsphere technology used by Fesarius Therapeutics at LBMS.
Brett Spector, Co-Founder and CEO
Since its founding, Mr. Spector has overseen all strategic and operational activities of the Company. In addition to his role at Fesarius, Mr. Spector is also the founder and Principal of RunUrFund LLC, a consultancy that provides turnkey startup services to start-up long-short hedge fund managers using a standardized methodology he developed based on Bloomberg and Microsoft Office365 tools. Prior to co-founding FesariusTherapeutics and RunUrFund, Mr. Spector was the CFO and CCO at Tide Point Capital Management LP, a long-short hedge fund he helped found in April 2012 which grew from under $30 million at launch to over $800 million in assets under management at the time of his departure in April 2015. Before Tide Point, Mr. Spector was the President and COO of SuttonBrook Capital Management LP, a multi-strategy hedge fund with peak assets under management of approximately $2.8 billion, which he also helped co-found in April 2002. Prior to SuttonBrook, Brett served as the CFO and CTO of several successful start-up and private companies. He began his career in the Financial Advisory Services Group at Coopers & Lybrand. Mr. Spector earned his M.B.A. from the University of Texas at Austin in 1990 and a B.A. in Economics cum laude from Drew University in 1988.
Dr. Yulia Sapir-Lekhovitser, Chief Scientific Officer
Prior to joining Fesarius Therapeutics, from January 2016 to July 2017, Dr. Sapir-Lekhovitser was a Research Scientist at Cresilon Inc., a NYC-based developer and manufacturer of a next generation surgical hemostat. As Cresilon’s most senior scientist, she led research activities in R&D operations, driving Cresilon’s investigation and product development in rheology and polymer science. She also played a significant role in the research management and technology transfer efforts, serving as subject matter expert in collaborating with the quality control, quality assurance, manufacturing and regulatory affairs departments.
Prior to joining Cresilon, from 2009 until August 2015, she was a doctoral student at Ben-Gurion University of the Negev, Beer Sheva, Israel, where she studied at the School of Biotechnology Engineering, supervised by Professor Smadar Cohen. For her thesis, she designed and developed novel composite biomaterials for mammalian cell cultivation and for stimulation within magnetic fields. Additionally, she designed a novel technique utilizing an atomic force microscope that enabled movement measurements of scaffolds within a magnetic field on 3-dimesional magnetic samples. Additionally, during this time, over a 14-month period between 2009-2012, she was a visiting researcher at Drexel University College of Medicine in Philadelphia, Pennsylvania, where she was supervised by Dr. Boris Polyak.
Dr. Sapir-Lekhovitser has authored 8 peer-reviewed publications, including 2 book chapters, and a book related to biomaterials and their use in tissue engineering.
Adam Weisel, Research Scientist
Prior to starting his position at Fesarius Therapeutics, Adam served as a research associate in the Chemical Chemodynamic Laboratories (CCL), an academic research group within the Environmental Occupational Health Sciences Institute, at Rutgers University. In that role, he worked to develop multi-scale, computational models of environmental and biological systems. In order to provide a better understanding and prediction of nanoparticle toxicity, he applied fundamental biological and chemical engineering principles to investigate computer based simulations of particle pulmonary dosimetry. This burgeoning, computational approach he was developing allows for a thorough view of toxicity that would be difficult to measure for commonly used, but scarcely studied nanoparticle systems.
In May 2016 Adam graduated from the University of Pennsylvania’s School of Engineering and Applied Science cum laude with his B.S.E. in Chemical and Biomolecular Engineering. As his capstone engineering project, he worked to develop a small, on-faucet device for automated arsenic detection in drinking water. He created a novel means for spatiotemporal tracking of the Center for Disease Control’s number one toxin in American water with a focus on both private consumer and researcher applications. Additionally, as an undergraduate, Adam served as a research associate in laboratories where he investigated varying stages and properties of bacterial film formation at oil-water interfaces with microfluidics and lithography, predictive computer models for safety shutdowns systems in varying processes, and methods of genetic recombination in biotechnological settings.
Davinder Sandhu, Associate
While currently completing his PhD at Weill Cornell, Davinder supports Brett Spector in an administrative and creative capacity with respect to the business development activities of the company. He works on projects ranging from website design and management, marketing materials development, scheduling, market research and assisting with research, scheduling and logistics relating to Mr. Spector’s fund raising and strategic relationship activities.
Davinder is a PhD candidate working in the laboratory of Dr. Steven Gross, where his thesis work is utilizing metabolomics to study the metabolism of patients with sporadic Amyotrophic Lateral Sclerosis. His academic career started at Rutgers University, where he graduated in 2009 with a Bachelor of Science in Biotechnology with an emphasis on bioinformatics. He then received his Master of Biotechnology from the University of Pennsylvania’s School of Engineering in the Fall of 2010, having done his thesis work in the lab of Dr. Brian Gregory, where he studied the role of the RNA polymerase V in the RNA-induced silencing complex. Prior to starting at Weill Cornell Medicine, Davinder was a High-Throughput Sequencing Specialist at University of Pennsylvania’s Penn Genome Frontiers Institute until 2012.